Home LiteratureArticle Details
PMID: 20542985 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Cytotoxicity of activated natural killer cells against pediatric solid tumors.

Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D

Abstract

To develop new therapies for children with solid tumors, we tested the cytotoxicity of natural killer (NK) cells expanded by coculture with K562-mb15-41BBL cells. We sought to identify the most sensitive tumor subtypes, clarify the molecular interactions regulating cytotoxicity, and determine NK antitumor potential in vivo. We tested in vitro cytotoxicity of expanded NK cells against cell lines representative of Ewing sarcoma (EWS; n = 5), rhabdomyosarcoma (n = 4), neuroblastoma (n = 3), and osteosarcoma (n = 3), and correlated the results with expression of inhibitory and activating NK receptor ligands. We also compared expanded and primary NK cells, determined the effects of activating receptor ligation and of chemotherapeutic drugs, and assessed the therapeutic effect of NK cell infusions in xenografts. In 45 experiments, EWS and rhabdomyosarcoma cell lines were remarkably sensitive to expanded NK cells, with median cytotoxicities at 1:1 effector/target ratio of 87.2% and 79.1%, respectively. Cytotoxicity was not related to levels of expression of NK receptor ligands, nor was it affected by pretreatment of target cells with daunorubicin or vincristine, but was markedly inhibited by preincubation of NK cells with a combination of antibodies against the NK-activating receptors NKGD2 and DNAM-1. Expanded NK cells were considerably more cytotoxic than unstimulated NK cells, and eradicated EWS cells engrafted in nonobese diabetic/severe combined immunodeficient Il2rgnull mice. Among pediatric solid tumors, EWS and rhabdomyosarcoma are exquisitely sensitive to expanded NK cells. The NK expansion method described here has been adapted to large-scale conditions and supports a phase I clinical study including patients with these malignancies.

MeSH Terms
Adolescent Animals Cell Line, Tumor Child Cytotoxicity, Immunologic Humans Immunotherapy, Adoptive/methods Killer Cells, Natural/immunology Lymphocyte Activation/immunology Male Mice Mice, SCID Neoplasms/immunology,therapy Neuroblastoma/therapy Osteosarcoma/therapy Rhabdomyosarcoma/immunology,therapy Sarcoma, Ewing/immunology,therapy Xenograft Model Antitumor Assays
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Cho Duck
Department of Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.
Shook David R
Shimasaki Noriko
Chang Yu-Hsiang
Fujisaki Hiroyuki
Campana Dario
References (48)
48 references, click to expand
  1. Replicative potential of human natural killer cells.
    Br J Haematol. 2009 Jun;145(5):606-13 PMID: 19344420
  2. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors.
    Blood. 2003 Aug 1;102(3):814-9 PMID: 12689936
  3. Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques.
    Cancer Genet Cytogenet. 2003 Mar;141(2):138-42 PMID: 12606131
  4. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells.
    J Immunol. 2005 May 15;174(10):6477-89 PMID: 15879151
  5. ERG gene is translocated in an Ewing's sarcoma cell line.
    Cancer Genet Cytogenet. 1994 Aug;76(1):19-22 PMID: 8076344
  6. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.
    Nature. 1986 Feb 20-26;319(6055):675-8 PMID: 3951539
  7. KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors.
    Pediatr Blood Cancer. 2009 Jul;53(1):120-4 PMID: 19215002
  8. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults.
    J Clin Oncol. 2003 Sep 15;21(18):3423-30 PMID: 12972518
  9. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.
    Blood. 2005 Jul 1;106(1):376-83 PMID: 15755898
  10. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.
    Lancet Oncol. 2005 Sep;6(9):649-58 PMID: 16129365
  11. Bone tumors: osteosarcoma and Ewing's sarcoma.
    Curr Opin Pediatr. 2009 Jun;21(3):365-72 PMID: 19421061
  12. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.
    Blood. 2005 Apr 15;105(8):3051-7 PMID: 15632206
  13. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.
    Blood. 2005 Jun 15;105(12):4878-84 PMID: 15731175
  14. Determinants of antileukemia effects of allogeneic NK cells.
    J Immunol. 2004 Jan 1;172(1):644-50 PMID: 14688377
  15. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups.
    J Clin Oncol. 2008 May 10;26(14):2384-9 PMID: 18467730
  16. Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12.
    Blood. 1994 Mar 1;83(5):1323-8 PMID: 7906963
  17. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy.
    Acta Oncol. 2005;44(7):748-55 PMID: 16227167
  18. Two established in vitro cell lines from human mesenchymal tumours.
    Int J Cancer. 1967 Sep 15;2(5):434-47 PMID: 6081590
  19. Unravelling natural killer cell function: triggering and inhibitory human NK receptors.
    EMBO J. 2004 Jan 28;23(2):255-9 PMID: 14685277
  20. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method.
    Cancer Gene Ther. 2010 Mar;17(3):147-54 PMID: 19745843
  21. Cultivation in vitro of cells derived from a human rhabdomyosarcoma.
    Cancer. 1969 Sep;24(3):520-6 PMID: 4241949
  22. Cultivation in vitro of cells derived from a human osteosarcoma.
    Cancer. 1971 Feb;27(2):397-402 PMID: 5100401
  23. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
    J Clin Oncol. 2004 Jul 15;22(14):2873-6 PMID: 15254055
  24. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group.
    J Clin Oncol. 2000 Sep;18(17):3108-14 PMID: 10963639
  25. Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group.
    J Clin Oncol. 2009 Aug 1;27(22):3705-11 PMID: 19470937
  26. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group.
    Pediatr Blood Cancer. 2008 Sep;51(3):334-8 PMID: 18506764
  27. Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies.
    Cancer. 2007 Jul 15;110(2):375-84 PMID: 17569105
  28. NK cell recognition.
    Annu Rev Immunol. 2005;23:225-74 PMID: 15771571
  29. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.
    Science. 2002 Mar 15;295(5562):2097-100 PMID: 11896281
  30. IL-17 enhances the susceptibility of U-2 OS osteosarcoma cells to NK cell lysis.
    Clin Exp Immunol. 2003 Sep;133(3):344-9 PMID: 12930359
  31. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.
    J Clin Oncol. 2009 Mar 1;27(7):1007-13 PMID: 19171716
  32. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction.
    Cancer Res. 2004 Dec 15;64(24):9180-4 PMID: 15604290
  33. Lymphokine-activated killer cytotoxicity in neonatal mononuclear cells: in vitro responses to tumor cell lines from pediatric solid tumors.
    Pediatr Res. 1989 Feb;25(2):156-60 PMID: 2537488
  34. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
    J Clin Oncol. 2010 Feb 20;28(6):955-9 PMID: 20085940
  35. Natural killer cells in children with malignant solid tumors. Effect of recombinant interferon-alpha and interleukin-2 on natural killer cell function against tumor cell lines.
    Cancer. 1989 Jan 1;63(1):83-9 PMID: 2783377
  36. 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells.
    Clin Cancer Res. 2009 Aug 1;15(15):4857-66 PMID: 19638467
  37. Differential response of cultured human normal and tumor cells to trace element-induced resistance to the alkylating agent melphalan.
    Cancer Res. 1985 Jun;45(6):2567-71 PMID: 4039221
  38. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.
    Cancer Res. 2009 May 1;69(9):4010-7 PMID: 19383914
  39. Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice.
    Cancer Immunol Immunother. 2007 Nov;56(11):1733-42 PMID: 17426969
  40. SK-NEP-1 and Rh1 are Ewing family tumor lines.
    Pediatr Blood Cancer. 2008 Mar;50(3):703-6 PMID: 17154184
  41. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture.
    Cancer Res. 1973 Nov;33(11):2643-52 PMID: 4748425
  42. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
    Clin Cancer Res. 2006 Mar 15;12(6):1750-9 PMID: 16551859
  43. The pediatric preclinical testing program: description of models and early testing results.
    Pediatr Blood Cancer. 2007 Dec;49(7):928-40 PMID: 17066459
  44. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
    Mol Immunol. 2008 Sep;45(15):3917-25 PMID: 18657862
  45. Hyperthermia increases the susceptibility of chondro- and osteosarcoma cells to natural killer cell-mediated lysis.
    Anticancer Res. 2002 Mar-Apr;22(2A):789-92 PMID: 12014651
  46. Human interferon: mass production in a newly established cell line, MG-63.
    Antimicrob Agents Chemother. 1977 Jul;12(1):11-5 PMID: 883813
  47. Ewing's sarcoma: ex vivo sensitivity towards natural and lymphokine-activated killing.
    Oncology. 1988;45(6):437-43 PMID: 3263598
  48. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy--a report from the Children's Oncology Group.
    Pediatr Blood Cancer. 2007 Dec;49(7):894-900 PMID: 17584910
Article Info
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Abbr.
Clin Cancer Res
ISSN
1557-3265
Published
2010-08-01
Epub
2010-00-11
Pages
3901-9
Language
English
Region
United States
NLM ID
9502500
PMCID
PMC3168562
Subset
IM
Grants
NCI NIH HHS · T32 CA070089 · United States
NCI NIH HHS · CA21765 · United States
NCI NIH HHS · R01 CA113482-05 · United States
NCI NIH HHS · P30 CA021765 · United States
NCI NIH HHS · R01 CA113482 · United States
NCI NIH HHS · CA113482 · United States
NCI NIH HHS · T32 CA070089-03 · United States
NCI NIH HHS · P30 CA021765-33 · United States
NCI NIH HHS · CA70089 · United States
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com